COMMUNIQUÉS West-GlobeNewswire

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
27/04/2026
PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical naïve and [...]
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
27/04/2026
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving [...]
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
27/04/2026
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that five [...]
Rgenta Therapeutics Announces Two Oral Presentations Highlighting Proprietary RSwitch Technology at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
27/04/2026
WOBURN, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for [...]
Beta Bionics to Present at the Bank of America Securities Health Care Conference
27/04/2026
IRVINE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at the [...]
Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal
27/04/2026
WARREN, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced continued progress within its artificial intelligence initiative, Tevogen.AI, including [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
27/04/2026
Déclaration de transactions sur actions propres Paris, France (27 avril 2026, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 30 avril 2025, EssilorLuxottica déclare que le 24 avril 2026, les [...]
IBA – ACQUISITION OF OWN SHARES
27/04/2026
Louvain-la-Neuve, Belgium, April 27 th , 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) [...]
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
27/04/2026
Ghent, Belgium, April 27, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE - REGULATED INFORMATION 27 April 2026, 6:00 pm CEST Ghent, Belgium, 27 April 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " [...]
AB Science annonce un accord final sur la renégociation des modalités de remboursement de ses emprunts avec l’ensemble de ses créanciers financiers
27/04/2026
COMMUNIQUE DE PRESSE AB SCIENCE annonce un accord final sur la renégociation des modalités de remboursement de ses emprunts avec l’ensemble de ses créanciers financiers AB Science est parvenue à un accord définitif avec [...]
AGC Biologics Wins 2026 Fierce Outsourcing Award for Leadership in Regulatory and Quality Compliance
27/04/2026
Global CDMO recognized for exceptional quality systems and regulatory track record; named finalist in Excellence in Client Service & Partnership and Manufacturing Operations categories SEATTLE, April 27, 2026 (GLOBE [...]
EssilorLuxottica: Disclosure of transactions in own shares
27/04/2026
Disclosure of transactions in own shares Paris, France (April 27, 2026 - 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 30, 2025, EssilorLuxottica declares that on [...]
Virbac : Public release of Virbac Annual Report at 31 December 2025.
27/04/2026
Public release of Virbac Annual Report at 31 December 2025. The Group released and filed its 2025 Annual Report with the French “Autorité des marchés financiers”, at the ESEF format. Additionally, the report is attached [...]
Virbac : Rapport Annuel Virbac au 31 décembre 2025 (ESEF)
27/04/2026
Veuillez trouver le Rapport Annuel du Groupe au format ESEF au 31 décembre 2025 Pièce jointe Rapport_Annuel_Virbac_2025_XBRL
IBA – ACQUISITION D’ACTIONS PROPRES
27/04/2026
Louvain-la-Neuve, Belgique, 27 avril 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") [...]
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors
27/04/2026
PRESS RELEASE AB SCIENCE announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors AB Science has reached a final agreement with its financial creditors [...]
Virbac : Communiqué de mise à disposition du Rapport Annuel de Virbac au 31 décembre 2025
27/04/2026
Communiqué de mise à disposition du Rapport Annuel de Virbac au 31 décembre 2025. Le Groupe annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers son Rapport Annuel au format [...]
Solana Company (NASDAQ: HSDT) Announces Registered Direct Offering of Common Stock to Global Institutional Investor
27/04/2026
NEWTOWN, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (“HSDT” or the “Company”), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to [...]
MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling
27/04/2026
On April 22, 2026, the U.S. Department of Justice and Drug Enforcement Administration’s final order rescheduling FDA-approved cannabis drug products and state-licensed medical cannabis from Schedule I to Schedule III of [...]

Pages